What's new? Log in Free sign up

Purple Biotech (PPBT)

Company Profile

Company profile

Ticker

PPBT

Exchange

Website

purple-biotech.com

CEO

Mr. Gil Efron CPA, M.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Kitov Pharma Ltd., Kitov Pharmaceuticals Holdings Ltd.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

PPBT stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Report of Foreign Private Issuer

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Report of Foreign Private Issuer

Prospectus supplement for primary offering

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Reports Third Quarter 2024 Financial Results

Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Latest ownership filings

View all

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL, LLC

CVI Investments, Inc.

SABBY MANAGEMENT, LLC

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL, LLC

SABBY MANAGEMENT, LLC

Financial summary

Financial statements Chart PPBT financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2023

PPBT institutional ownership history Ownership history

6.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	17	16	+6.3%
Opened positions	5	4	+25.0%
Closed positions	4	5	-20.0%
Increased positions	4	1	+300.0%
Reduced positions	2	3	-33.3%

13F shares	Current	Prev Q	Change
Total value	373.99 mm	182.25 mm	+105.2%
Total shares	1.62 mm	1.47 mm	+10.5%
Total puts	3.50 k	4.20 k	-16.7%
Total calls	39.80 k	65.70 k	-39.4%
Total put/call ratio	0.1	0.1	+37.6%

Largest owners	Shares	Value	Change
CVI Investments	1.35 mm	$5.14 mm	0.0%
Kingswood Wealth Advisors	127.95 k	$178.49 mm	NEW
Citadel Advisors	45.94 k	$64.32 mm	+202.8%
MS Morgan Stanley	29.63 k	$41.34 mm	+28.3%
Venture Visionary Partners	13.72 k	$19.14 mm	+5.0%
Wealth Advisors of Iowa	13.27 k	$18.51 mm	+6.1%
Geode Capital Management	12.67 k	$17.73 mm	0.0%
Raymond James & Associates	11.00 k	$15.35 mm	0.0%
Simplex Trading	9.16 k	$12.00 k	-53.5%
Fiduciary Alliance	5.41 k	$7.55 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Kingswood Wealth Advisors	127.95 k	+127.95 k	NEW
Citadel Advisors	45.94 k	+30.77 k	+202.8%
Simplex Trading	9.16 k	-10.55 k	-53.5%
MS Morgan Stanley	29.63 k	+6.54 k	+28.3%
Fiduciary Alliance	5.41 k	+5.41 k	NEW
UBS UBS	0.00	-4.57 k	EXIT
Belpointe Asset Management	0.00	-2.60 k	EXIT
Ameritas Advisory Services	0.00	-1.00 k	EXIT
Wealth Advisors of Iowa	13.27 k	+765.00	+6.1%
Venture Visionary Partners	13.72 k	+650.00	+5.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Why Purple Biotech (PPBT) Stock Is Getting Hammered

Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes.

Purple Biotech Reported Final Results From Phase 2 Study Of Its Lead Oncology Drug, CM24, In Patients With Pancreatic Ductal Adenocarcinoma

HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target

Press releases

From Benzinga Pro

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune

Purple Biotech Reports Third Quarter 2024 Financial Results

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.